ngenla
(somatrogon-ghla)Pfizer Laboratories Div Pfizer Inc
Usage: NGENLA is indicated for treating pediatric patients aged 3 years and older with growth failure resulting from inadequate secretion of endogenous growth hormone.
4 results
norditropin
(somatropin)Novo NordiskUsage: NORDITROPIN is indicated for pediatric patients with growth failure from inadequate growth hormone secretion, short stature due to Noonan or Turner syndrome, short stature born SGA, Idiopathic Short Stature, and Prader-Willi syndrome. For adults, it is used to replace endogenous growth hormone in those with deficiency.skytrofa
(Lonapegsomatropin-tcgd)Ascendis Pharma Endocrinology, Inc.Usage: SKYTROFA (lonapegsomatropin-tcgd) is indicated for treating pediatric patients aged 1 year and older, weighing at least 11.5 kg, with growth failure caused by inadequate secretion of endogenous growth hormone (GH).sogroya
(somapacitan-beco)Novo NordiskUsage: SOGROYA is indicated for treating pediatric patients aged 2.5 years and older with growth failure due to inadequate growth hormone secretion and for replacing endogenous growth hormone in adults with growth hormone deficiency.